Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.

Seongju JeongEunyoung ParkHyung-Don KimEunsil SungHyunjoo KimJaehyoung JeonYoungkwang KimUi-Jung JungYong-Gyu SonYoungeun HongHanbyul LeeShinai LeeYangmi LimJonghwa WonMinwoo JeonShin HwangLei FangWenqing JiangZhengyi WangEui-Cheol ShinSu-Hyung ParkJaeho Jung

Published in: Journal for immunotherapy of cancer (2022)

The novel anti-4-1BB×PD-L1 bispecific antibody may exert a strong anti-tumor therapeutic efficacy with a low risk of liver toxicity through the restriction of 4-1BB stimulation in tumors.

Keyphrases

growth factor
recombinant human
dna damage
oxidative stress
cell cycle
cell proliferation